What's Next for DTC Telehealth in 2025?
Expect a surge in virtual wellness and retailer-led health brands
The growth of direct-to-consumer (DTC) telehealth services over the last few years is undeniable and isn’t expected to slow down anytime soon. This model of care offers patients fast and convenient access to services often hindered by industry middlemen.
With chronic conditions on the rise and provider shortages intensifying, the demand for virtual care will continue to grow. However, in 2025, the virtual wellness space will take center stage in DTC telehealth, driving the next wave of industry expansion.
DTC telehealth expansion factors in 2025
Common barriers to care—such as transportation, clinician shortages, work-related constraints, and stigma—often prevent people from seeking in-person care. However, DTC telehealth minimizes or eliminates many of these access challenges. Patients don’t even need insurance to utilize many of these services, and several find them significantly more affordable.
Cost savings, along with other factors, have fueled the rapid adoption of this telehealth model in recent years. Several key trends point to a strong future for telehealth:
The U.S. population is aging
Chronic conditions, such as obesity, are increasing
Health technology, like RPMs and AI, is advancing
More people prefer aging in place rather than moving to a nursing facility
Rural areas continue to face physician shortages
Consumers have grown comfortable with virtual care since the COVID-19 pandemic
Now, let’s dive into what DTC telehealth is trending towards in 2025.
Non-traditional retailers entering the DTC telehealth market
Retail health providers like Walgreens and CVS have rapidly expanded their DTC telehealth services to meet consumer demand for convenient, personalized care.
However, looking ahead to 2025, non-traditional retailers will increasingly enter the DTC telehealth space—not just as service providers, but as creators of their own digital health brands.
By partnering with digital health organizations, these companies will launch private-label telehealth services, leveraging their brand trust, vast customer networks and existing infrastructure to drive new revenue streams.
Expect major players across industries to integrate virtual care solutions into their offerings, further expanding healthcare accessibility.
Expect a rise in virtual wellness in 2025
Telemedicine is accelerating the growth of DTC wellness, with more brands offering personalized, at-home treatments for common health concerns.
Companies like Hims & Hers®, Fridays® and Ro® have paved the way, making virtual care for erectile dysfunction, weight loss, hair loss, skincare and mental health more accessible than ever. As consumers increasingly prioritize convenience and discretion in their healthcare choices, more retailers and digital health startups are expected to enter the market with specialized, subscription-based wellness solutions.
As demand for virtual wellness surges, 2025 is set to bring a wave of new innovations, making digital-first healthcare more mainstream than ever before.
DTC telehealth for TRT services
The market for testosterone replacement therapy (TRT) was $2.04 billion in 2024 and is expected to grow to $2.1 billion in 2025 at a compound annual growth rate (CAGR) of 2.7%. The rising demand for TRT services is fueled by increased awareness, an aging population, rising obesity rates and the expansion of telehealth.
A 2021 study found that telemedicine for TRT improved access to care, reduced costs, and enhanced patient satisfaction. A later 2022 study examined the characteristics of men utilizing DTC men’s health services, like Hims® and Roman®. Researchers found that middle-aged men in the middle-income bracket were the most likely users, though younger men also turned to DTC options due to the lack of a primary care physician.
Major brands are recognizing this demand, with The Vitamin Shoppe partnering with a pharmaceutical company in late 2024 to launch TRT services. Other companies, such as LifeMD and Tolmar, have also expanded into the space.
Accessing virtual HRT services
Like TRT, the hormone replacement therapy (HRT) market is expected to grow. In 2022, the U.S. HRT market was valued at $6.9 billion and is projected to reach $13.4 billion by 2032.
In June 2023, it was reported that menopause care remained a largely untapped market. Since then, telehealth providers have stepped in to bridge this critical healthcare gap, expanding access to much-needed care.
A 2022 survey revealed that:
40% of women reported that menopause symptoms interfered with their work performance.
25% felt that menopause symptoms negatively impacted their career development.
57% said it was important for their employer to support employees experiencing menopause symptoms.
Virtual HRT services will continue to gain traction in 2025, with new collaborations already taking shape. For example, Evernow, a leading digital health platform for women, has partnered with Clearblue. Users of the Clearblue® Menopause Stage Indicator can seamlessly connect with an Evernow menopause-trained professional for personalized, ongoing care.
DTC telehealth accommodates GLP-1 growth
The buzz around glucagon-like peptide-1 (GLP-1) receptor agonists continues to grow, thanks to the accessibility of DTC telehealth.
In 2025, compounded GLP-1 options will gain traction due to their affordability and expanded medication types. Virtual care has already proven to be an attractive option for patients seeking these treatments, a trend that will continue in the coming year.
To accommodate this growth, more drug developers are entering the DTC telehealth space. Eli Lilly, for instance, is connecting patients to providers for access to medications for diabetes, obesity and migraines. Pfizer, Amazon Pharmacy and other digital health pharmacy platforms are also helping patients bypass traditional pharmacies and in-person doctor visits.
Hair loss addressed via DTC telehealth
A 2023 study revealed that patients believe DTC teledermatology enhances hair appearance and self-esteem. The Journal of the American Academy of Dermatology’s January 2025 publication also highlighted the benefits of DTC platforms for androgenetic alopecia, including:
More cost-effective medication for uninsured patients with high copays.
Faster access to treatment compared to traditional dermatology.
High patient satisfaction with overall care.
According to BioSpace, the alopecia areata market is expected to grow at a CAGR of 6.12% between 2025 and 2035, driven by the adoption of telemedicine platforms and AI-powered diagnostic tools.
ED treatment via virtual care
The demand for discreet and convenient erectile dysfunction (ED) treatment is increasing, driven by digital health platforms.
The ED drug market was approximately $2.92 billion in 2024 and is projected to grow at a CAGR of 9.13% from 2025 to 2030. The entry of major companies into the space signals this growth—Amazon One Medical, for example, launched ED services in late 2024, competing with Ro, Hims & Hers and others.
Seamlessly launch your own DTC telehealth brand
As companies look ahead to 2025, many are looking to capitalize on the booming demand for virtual care. Consumers are increasingly seeking accessible DTC healthcare solutions for everything from ED and weight loss to hair loss and mental health.
At OpenLoop, we make launching a DTC telehealth offering effortless with our fully managed, white-labeled infrastructure. From clinical operations and regulatory compliance to billing, medication management, and legal oversight—we handle it all. You focus on building your brand and engaging your audience; we take care of the rest.
Interested in learning more? Get in touch here!
Our full suite of white-labeled virtual care infrastructure solutions include: